Bartlett & Co’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Bartlett & Co’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-600	Closed	-$3K	–	1307
2022 Q1	$3K	Buy	+600	New	+$3.57K	﹤0.01%	969

Other funds holding SGMO

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

RCMU

Rokos Capital Management (UK) London, United Kingdom $13.2B AUM 85.71% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bartlett & Co's SGMO Position: Q2 2022 in Review

Bartlett & Co sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q2 2022, closing a stake of 600 shares — an estimated $3K sold.

Bartlett & Co first reported a position in SGMO in Q1 2022 and held it in 1 quarter. The position peaked at $3K in Q1 2022. 188 funds tracked by Wall St. Rank hold SGMO as of Q2 2022.

Bartlett & Co reported no remaining SANGAMO THERAPEUTICS INC position as of Q2 2022 after selling out during the quarter.
Bartlett & Co sold 600 SANGAMO THERAPEUTICS INC shares in Q2 2022, an estimated $3K.
Bartlett & Co first reported a position in SANGAMO THERAPEUTICS INC in Q1 2022 and held it in 1 quarter.
Bartlett & Co's SANGAMO THERAPEUTICS INC position peaked at $3K in Q1 2022.
188 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q2 2022.

Based on Bartlett & Co's 13F filing for Q2 2022, filed 2 Aug 2022.